Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme -- Ignore unavailable to you. Want to Upgrade?

To: Logistics who wrote (6150)	6/30/1998 2:55:00 PM
From: TokyoMex	Respond to of 8798

I see it !!!! Bought 5,000 11 1/8 for tomorrow's gappa ,, ggg sold 10,000 at 10 1/2 ,, because I was in a blind spot with my confirmation with E-Trade..

To: Logistics who wrote (6150)	6/30/1998 2:57:00 PM
From: TokyoMex	Respond to of 8798

Nasal-Spray Flu Shot Helps Prevent Infection in Children By ROBERT LANGRETH Staff Reporter of THE WALL STREET JOURNAL Government researchers said a new nasal spray vaccine for the influenza virus prevented flu in a large test in children, possibly paving the way for a new class of easily administered vaccines for large numbers of patients. The new vaccine could make it easier to vaccinate many more children, experts said. Unlike other vaccines, the new one doesn't require an injection, merely two quick sprays of the medicine in each nostril. The vast majority of healthy children don't now get flu shots, in part because children find shots unpleasant. OTHER RESOURCE The National Institute of Health: nih.gov And the vaccine, which was developed by the National Institutes of Health and Aviron, a small biotechnology company based in Mountain View, Calif., is expected to cost no more than regular vaccines delivered by injection. Researchers involved in the project said that such nasal vaccines, if approved by the Food and Drug Administration, could lead to the development of similar vaccines for other respiratory diseases, including viral pneumonia and croup. Aviron expects to apply next year for government approval to market the vaccine to both children and adults, and it plans to have the product available for the 1999 winter flu season. Shares of Aviron jumped $3.75, or 28%, to $17.125 in Nasdaq trading, after the trial results were announced. "This is at least as good, if not better" in efficacy than current flu shots, but much easier to use, said Robert Belshe, an infectious-disease specialist at St. Louis University, who helped run the tests. "It could have a major public health impact." In particular, researchers said that the nasal vaccine, if it catches on, could help reduce the flu season's overall severity by preventing new strains from catching on among schoolchildren. "Influenza circulates in schoolchildren, who then bring it home and pass it on to adults. If you dampen the spread of the virus in children, you may also slow the spread in adults" and high-risk groups such as the elderly, said Dominick Iacuzio, who heads flu research at the National Institutes of Health. In the Aviron test, 1,602 children were given either two doses of the Aviron vaccine or a placebo prior to last year's flu season. Only 1% of the children who received the vaccine developed flu, compared with 18% who received the placebo. Overall, the vaccine was 93% effective in preventing disease. The Aviron trial didn't directly compare the new vaccine to flu shots, but according to government estimates shots are 70% to 90% effective in people under the age of 65. Besides the new vaccine-delivery method, the Aviron vaccine differs fundamentally from existing vaccines in that it uses a weakened form of the living influenza virus -- rather than a dead virus in current flu shots -- to generate an immune response. This so-called "attenuated virus" is safe because it has been altered only to survive in the relatively cool nasal passages, but it can't grow in the warmer parts of the lung and throat that influenza viruses usually infect. Each year 35 million to 50 million Americans get the flu, and some 20,000 die from the virus, according to federal statistics.